G. Walmsley Graham - Sep 12, 2023 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OLMA	Common Stock	Purchase	$5M	+508K	+43.8%	$9.84	1.67M	Sep 12, 2023	See note	F1
transaction	OLMA	Common Stock	Purchase	$470K	+31.9K	+1.91%	$14.73	1.7M	Dec 5, 2023	See note	F1
transaction	OLMA	Common Stock	Purchase	$747K	+50K	+2.94%	$14.95	1.75M	Dec 5, 2023	See note	F1
transaction	OLMA	Common Stock	Purchase	$654K	+50K	+2.86%	$13.09	1.8M	Dec 5, 2023	See note	F1
holding	OLMA	Common Stock						1.4M	Sep 12, 2023	See note	F2
holding	OLMA	Common Stock						1.18M	Sep 12, 2023	See note	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the reporting person is a managing member of Logos GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F2	The shares are held by Logos Opportunities Fund I LP ("Logos Fund I"). Logos Opportunities GP, LLC ("Logos Opportunities GP") is the general partner of Logos Fund I and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F3	The shares are held by Logos Opportunities Fund II LP ("Logos Fund II"). Logos Opportunities GP is the general partner of Logos Fund II and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.